natgillin/translations-raw huggingface dataset:
The liquid phases were separated, the organics were washed with brine, dried over MgSO4, filtered and evaporated to yield a solid. 
Tekuće faze se razdvoje, organski dio ispere s fiziološkom otopinom, osuši preko MgSO,, filtrira i upari da se dobije krutina.
A process according to claim 1, comprising, as a partial alternative to point a. the following steps: 
Postupak prema patentnom zahtjevu 1, naznačen time, da su djelomična alternativa točki a., nakon reakcije amina
The polypeptide of any one of claims 1-4, comprising an amino acid sequence at least 95% identical to an amino acid sequence according to SEQ ID NO:1 or SEQ ID NO:35. 
Polipeptid iz bilo kojeg od patentnih zahtjeva 1-4, koji sadrži aminokiselinsku sekvencu najmanje 95% identičnu aminokiselinskoj sekvenci u skladu sa SEK ID BR:1 ili SEK ID BR:35.
The method of claim 1, wherein the vaccine comprises tetanus toxoid adsorbed onto aluminium hydroxide, or aluminium phosphate, or a mixture of both, wherein adsorption takes place either before or after mixing with other antigens. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1-13, naznačen time što cjepivo sadrži difterijski toksoid i/ili tetanusni toksoid, adsorbiran na aluminijev hidroksid, ili aluminijev fosfat, ili smjesu istih, gdje se adsorciju provodi bilo prije ili nakon miješanja s drugim antigenima.
The animal of claim 1, further comprising at an endogenous non-human B2 microglobulin locus a nucleotide sequence encoding a human or humanized B2 microglobulin polypeptide, wherein the animal expresses the human or humanized B2 microglobulin polypeptide. 
Životinja prema zahtjevu 1, naznačena time, da nadalje na endogenom ne-humanom B2-mikroglobulin-lokusu, obuhvaća nukleotidnu sekvencu koja kodira humani ili humanizirani B2-mikroglobulin-polipeptid, pri čemu životinja izražava humani ili humanizirani B2-mikroglobulin-polipeptid.
After cooling, 30% sodium hydroxide solution (97 ml) was added to the reaction mixture followed by 30% hydrogen peroxide solution (48.6 ml) and the reaction was stirred and heated to reflux for an additional 1 hour. 
Nakon hlađenja, u reakcijsku smjesu se doda 30%-tna otopina natrij hidroksida (97 ml) i neposredno nakon toga doda se i 30%-tna otopina vodikovog peroksida (48.6 ml) te se reakcija miješa 1 zagrijava do refluksa tijekom dodatnih sat vremena.
This test measures the ability of a test compound to inhibit the phosphorylation of a tyrosine containing polypeptide substrate by EGFR or ErbB2 tyrosine kinase enzyme. 
Ovim trestom mjeri se sposobnost ispitivanog spoja da inhibira fosforilaciju polipeptidnog supstrata koji sadrži tirozin, od strane EGFR ili ErbB2 tirozin kinaze.
Process for the preparation of a mixture of bitumen having a high processabillity 
POSTUPAK DOBIVANJA BITUMENSKE SMJESE VISOKE OBRADIVOSTI
wherein a compound of formula (4): is allowed to react with hydrogen in the presence of a 5% palladium/1% iron catalyst on carbon which is water-wetted, in a solvent, thereby providing a compound of formula (5). 
O. (4) ' ostavljen da reagira s vodikom u prisutnosti 5% paladijevog/1% željezovog katalizatora na ugljiku koji je navlažen vodom, u otapalu, čime se dobiva spoj s formulom (5).
releasing the grip on the ladle shroud. 
HR P20180287 T1 na izljevniku.
The mouse of claim 8, wherein the first nucleotide sequence encodes a chimeric HLA-A/H-2K polypeptide, the second nucleotide sequence encodes an a chain of a chimeric HLA-DR/H-2E polypeptide, and the third nucleotide sequence encodes a B chain of a chimeric HLA-DR/H-2E polypeptide, and wherein the mouse expresses HLA-A/H-2K and HLA-DR/H-2E proteins. 
Miš prema zahtjevu 8, naznačen time, da prva nukleotidna sekvenca kodira kimerni HLA-A/H-2K-polipeptid, druga nukleotidna sekvenca kodira a-lanac kimernog HLA-DR/H-2E-polipeptida, 1 treća nukleotidna sekvenca kodira fB-lanac kimernog HLA-DR/H-2E-polipeptida, te time, da miš izražava HLA-A/H-2K-proteine i HLA-DR/H-2E-proteine.
m is 0-2; and n is 0-4. When R1 is phenyl or a 5 or 6 membered heteroaryl ring it may be substituted by up to three substituents selected from halogen, C(1-4)alkyl, C(1-4)alkoxy, trifluoromethoxy, difluoromethoxy, trifluoromethyl and cyano. 
X je izravna veza; m je 0-2; nje0-4;i kada R, je supstituirani fenil ili 5- ili 6-eročlani heteroarilni prsten, isti je supstituiran s do tri supstituenta, koje se neovisno bira između halogena, C(1.alkila, C(,.palkoksi, trifluormetoksi, difluormetoksi, trifluormetila 1 cijano.
For sanitization, the column was flushed with at least 6 BV of 1M NaOH, the flow stopped for 1 hour, and the column then rinsed with at least 6 BV of purified water. 
Za sterilizaciju, kolona je bila oprana s najmanje 6 BV IM NaOH, protok je zaustavljen nakon 1 sata, a kolona je tada oprana s najmanje 6 BV pročišćene vode.
The components (B) are known. 
(B) spoj fenpropidin.
The reaction was diluted with water, stirred for 10 min, and compound 37 was obtained as a red solid and collected by vacuum filtration. 
Reakcija se razrijedi vodom, miješa tijekom 10 min i dobiva se spoj 37 kao žuta krutina te prikupi pomoću vakuum filtriranja.
Embodiments of this invention comprise lyophilization by cooling product below −40° C. The primary drying is performed at a temperature from about −20° C. to about −26° C. and a pressure of about 60 ubar for approximately 15 to 40 hours. 
Varijante ovog izuma sadrže liofilizaciju hlađenjem proizvoda ispod -40*C. Primamo sušenje je izvedeno na temperaturi od oko -20%C do oko -26ĆC i pritisku od oko 60 ubar približno 15 do 40 sati.
An ODT as claimed in claim 1, wherein the at least one disintegrant is selected from the group consisting of crospovidone, sodium starch glycolate, crosslinked carboxymethyl cellulose, low-substituted hydroxypropylcellulose, mannitol, xylitol, sorbitol, maltol, maltitol, lactose, sucrose, maltose, and combinations thereof. 
Tableta za oralno disperziranje sukladno patentnom zahtjevu 6, naznačeno time da je najmanje jedno sredstvo za razgradnju se bira iz skupine koju čine krospovidon, natrijev škrobni glikolat, umrežene karboksimetil celuloze, nisko supstituiran hidroksilpropil celuloza, manitol, ksilitol, sorbitol, maltol, maltitol, laktoza, saharoza, maltoza, i njihove kombinacije.
The method of claim 12, wherein one of the 3 nucleotide differences in the nucleotide sequence of the antisense strand is a nucleotide mismatch in the seed region of the antisense strand, wherein preferably the antisense strand comprises a universal base at the mismatched nucleotide; and/or 
RNAi sredstvo ili farmaceutski pripravak za uporabu prema zahtjevu 12, naznačeno time da (a) jedna od 3 nukleotidne razlike u nukleotidnoj sekvenci protusmjernog lanca je nukleotidna neusklađenost u sjemenskoj regiji protusmjernog lanca, pri čemu protusmjerni lanac poželjno sadrži univerzalnu bazu na neusklađenom nukleotidu; i/ili
The method of claim 1, wherein the polypeptide is administered to the subject within seven days following the damage to or loss of nerve fibers. 
Polipeptid za uporabu kao u bilo kojem od zahtjeva 2-6, naznačen time, što polipeptid treba primijeniti kod subjekta u okviru sedam dana od oštećenja ili gubitka živčanih vlakana.
The composition of claim 3, optionally further comprising a mucolytic agent, as bronchodialator, an antibiotic, an anti-infective agent, an anti-inflammatory agent, a CFTR modulator, or a nutritional agent. 
Pripravak prema zahtjevu 19, naznačen time da nadalje sadrži mukolitičko sredstvo, bronhodilatator, antibiotik, protuinfektivno sredstvo, protuupalno sredstvo, modulator CFTR, ili prehrambeno sredstvo.
Cannabinoid receptors are expressed on lung epithelial cells. 
Kanabinoid receptori se ekspresiraju na stanicama plućnog epitela.
The antibody according to claim 11, wherein the antibody is an antigen binding fragment. 
Nukleinska kiselina, naznačena time, da kodira protutijelo prema patentnim zahtjevima od 1 do 5.
The compound of claim 4 or 5 wherein A2 is phenyl substituted with CO2H or tetrazolyl; and L is a direct bond; or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 4 ili 5, naznačen time što je A2 fenil, supstituiran s CO2H, ili tetrazolil; a L je izravna veza; ili njegova farmaceutski prihvatljiva sol.
), cooled to 0 to 5°C., acidified slowly to a pH below 1.0 with concentrated HCI and extracted with ethyl acetate (4 x 2 I. 
), ohladi se na 0 do 5"C, zakiseli se lagano na pH ispod 1.0 sa koncentriranom HC1 i ekstrahira se sa etilacetatom (4x2 1.
Medium of claim 1 for use in a method of assisted reproductive technology comprising the step of handling human reproductive cells with the substantially protein-free culture medium. 
Podloga prema patentnom zahtjevu 1 za uporabu u postupku asisitirane reproduktivne tehnologije koji sadrži korak rukovanja humanim reproduktivnim stanicama sa podlogom za kulturu značajno bez proteina.
The method of claim 1, wherein the cancer is selected from the group consisting of acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), breast cancer, cervical cancer, colorectal cancer, ganglioneuromatosis of the gastroenteric mucosa, gastric cancer, gastrointestinal stromal tumors, glioma, leukemia, lung cancer, lymphoma, multiple endocrine neoplasia type 2A or 2B (MEN2A or MEN2B, respectively), multiple myeloma, non-Hodgkin's lymphoma, non-small cell lung cancer, ovarian cancer, papillary renal cell carcinoma, paraganglioma, parathyroid hyperplasia, pheochromocytoma, and thyroid cancer. The method of claim 20, wherein the cancer is leukemia. 
Spoj, ili njegova farmaceutski prihvatljiva sol, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 17-18, naznačen time što rak povezan s RET se bira iz skupine koju čine: rak pluća, papilarni rak štitnjače, rak jezgre štitnjače, diferencirani rak štitnjače, recidivirajući rak štitnjače, rezistentan diferencirani rak štitnjače, multiple endokrine novotvorine tipa 2A ili 2B (MEN2A odnosno MEN2B), feokromocitom, hiperplazija nusštitnjače, rak dojke, kolorektalni rak, karcinom papilarnih bubrežnih stanica, ganglioneuromatoza želučanocrijevne sluznice, te rak vrata maternice.
Besides, beads obtained by a similar reaction without adding 4-amino-N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]butanamide hydrochloride were used as control beads. 
Derivat benzopirana za uporabu u skladu s patentnim zahtjevom 1, naznačen time, da je derivat benzopirana N-[7- [(metilsulfonil) amino]-4-okso-6-fenoksi-4H-1- benzopiran-3-il]formamid.
A vector comprising the nucleic acid molecule of claim 1 . The vector of claim 3, further comprising a nucleic acid molecule encoding a heterologous polypeptide. 
Vektor koji sadrži molekulu nukleinske kiseline iz patentnog zahtjeva 1, 2, ili 3, naznačena time, da poželjno dodatno sadrži molekulu nukleinske kiseline koja kodira heterologni polipeptid.
The precise effective amount for a subject will depend upon the subject's size and health, the nature and extent of the condition being treated, recommendations of the treating physician, and the therapeutics or combination of therapeutics selected for administration. 
Precizna učinkovita količina kod subjekta ovisit će o veličini subjekta i njegovu zdravlju, prirodi i stupnju stanja koje se liječi, liječnikovim uputama za liječenje i terapeuticima ili kombinaciji terapeutika koja je odabrana za liječenje.
A pharmaceutical composition as in claim 1 is used to treat traveler's diarrhea, hepatic encephalopathy, infectious diarrhea, diverticular disease, an antibacterial prophylactic prior to colon surgery, irritable bowel syndrome, Crohn's disease, Clostridum difficile-associated diarrhea, small intestinal bacterial overgrowth, traveler's diarrhea prophylaxis, dysentery, pouchitis, peptic ulcer disease, surgical prophylaxis and gastric dyspepsia. 
Oralni farmaceutski pripravak s kontroliranim oslobađanjem u skladu sa zahtjevom 1 naznačen time da je za uporabu u liječenju putnih proljeva, hepatičke encefalopatije, zaraznih proljeva, divertikularne bolesti, za antibakterijsku profilaksu prije operacije debelog crijeva, za liječenje sindroma nadražljivih crijeva, Crohnove bolesti, proljeva uzrokovanog bakterijom Clostridium difficile, prekomjernog broja bakterija u tankom crijevu, za profilaksu putnog proljeva, za liječenje dizenterije, pouchitisa (upale kirurški oblikovane crijevne vrećice), za predoperativnu profilaksu i za liječenje želučane dispepsije.
which is enriched in the corresponding (2R,3R)/(2S,3S) racemate, and wherein R1 and R2 are each fluoride or hydrogen and when R1 is fluoride, R2 is hydrogen and when R2 is fluoride, R1 is hydrogen, wherein R is a C1-C12 alkyl, a C5-C12 aryl or a C6-C11 aralkyl, 
(2R,38) koji se obogaćuje u odgovarajući (2R,3R)/(2S,3S) racemat, i pri čemu R, i R2 su svaki fluorid ili vodik i kada R, je fluorid, R> je vodik i kada R, je fluorid, R, je vodik, pri čemu R je Ci-Ci2 alkil, Cs-C1i2 aril ili Cs-Ci aralkil, koji sadrži korake
■ Isocratic, 40 minute run-time, flow-rate 0.5ml/min 
* = Izokratski, 40 minuta vrijeme razvijanja, brzina protoka 0,5 ml/min
Preferred groups R4 are the following: butyl; phenyl; 4-hydroxyphenyl; 4-methoxyphenyl; 4-methylphenyl; 3-chloro-4-hydroxyphenyl; 3-fluoro-4-hydroxyphenyl. Yet more preferably, R4 represents a 4-hydroxyphenyl group. 
Spoj formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time, da Ru predstavlja fenil, 4-hidroksifenil, 4-metoksifenil, 4-metilfenil, 3-klor-4-hidroksifenil ili 3-fluor-4-hidroksifenil skupinu .
The following compounds were synthesized according to the described procedure. 
Prema opisanim postupcima sintetizirani su slijedeći spojevi:
and R2, when attached to the same carbon atom, can combine to form cycloalkyl or monocyclic saturated heterocyclyl to give a spiro ring wherein the cycloalkyl or monocyclic saturated heterocyclyl can be optionally substituted with Rd, Re, or Rf independently selected from alkyl, alkoxy, fluoro, fluoroalkyl, fluoroalkoxy, hydroxy, monosubstituted amino, or disubstituted amino; or 
i R2, kada su vezani na isti atom ugljika, mogu se kombinirati i tvorili cikloalkil ili monociklički zasićeni heterociklil da se dobije spiro prsten pri čemu cikloalkil ili monociklički zasićeni heterociklil mogu biti proizvoljno supstituirani sa Rd, Rc ili Rf neovisno odabranim od alkila, alkoksi, fluoro, fluoroalkil, fluoroalkoksi, hidroksi, monosupstituiranim amino, ili disupstituiranim amino; ili
A gap (40) defined between the removable cover (48) and the lower part (56) is smaller than the bee, not allowing it to exit towards the top (10) of the lid. 
Raspor (40) je manji od pčele, pa ona ne može izaći prema gornjem dijelu (10) poklopca.
The control unit of claim 10, wherein said palm (40) or said finger (60) interface can be manipulated by a user when said minimally invasive surgical tool (12) is frozen in position. 
Kontrolna jedinica iz zahtjeva 10, naznačena time da navedeno sučelje za dlan (40) 1 navedeno sučelje upravljano dodirom prsta (60) mogu biti manipulirani od strane korisnika kad je naveden minimalno invazivan kirurški alat (12) zaustavljen u unaprijed postavljenoj poziciji.
A process for producing 3-chloro-N-(3-chloro-5-trifluoromethyl-2-pyridyl)-a,a,a-trifluoro-2,6-dinitro-p-toluidine, which comprises reacting 2-amino-3-chloro-5-trifluoromethylpyridine and 2,4-dichloro-3,5-dinitrobenzotrifluoride in the presence of an alkali component selected from the group consisting of sodium hydroxide and potassium hydroxide, a solvent selected from the group consisting of ketones, nitriles, ethers and esters and a substantial amount of water, wherein water is present in an amount of 20-40 mass/mass % in relation to the total of water and the solvent. 
3-kloro-N-(3-kloro-5-trifluorometil-2-piridil)-0.,a,a-trifluoro-2,6-dinitro-p-toluidina, naznačen time, da se sastoji od reakcije 2-amino-3-kloro-5-trifluorometilpiridina i 2,4-dikloro-3,5-dinitrobenzotrifluorida u nazočnosti alkalne komponente odabrane iz skupine koja se sastoji od natrijevog hidroksida i kalijevog hidroksida, otapala odabranog iz skupine koja se sastoji od ketona, nitrila, etera i estera te dovoljne količine vode za bitno otapanje alkalne komponente, pri čemu je voda nazočna u količini od 20-40% u odnosu na ukupnu količinu vode u otapalu.
The device as claimed in claim 1, further comprising a system configured to compress or aspirate one or both of the fluid component or the solid component of the fat into or from the washing chamber (101) of the washing and separating container (1) or the reducing chamber (201) of the size reducing container (2). 
Uređaj kao što je navedeno u jednom ili više prethodnih patentnih zahtjeva, naznačen time da su osigurana sredstva za kompresiju ili aspiraciju tekuće komponente i/ili čvrste komponente masti u ili iz komore za pranje (101) kontejnera za pranje i odvajanje (1) i/ili komore (201) za smanjivanje kontejnera (2) za smanjivanje veličine.
The apparatus works in such a way whereby the solution of container (A) will give place to a foam by blowing in air: this foam, which will act as a support or carrier, is mixed with the ureic resin solution, this latter, in the presence of the hardener, will harden giving place to a stable solid foam. 
- crpaljke, kompresora i pištolja za izradu pjene. Sprava djeluje tako, da nastaje iz otopine is posude (A) sa upuhavanjem zraka pjena; na toj pjeni, koja djeluje kao podupirač, porazdeli se otopina urinske smole, koja se stvrdi u prisutnosti katalizatora, kod toga se stvori stabilna čvrsta pjena,
The pharmaceutical dosage form of any one of claims 1 to 8, wherein the lower limit of 14-hydroxycodeinone is 5 ppm, 2 ppm, 1 ppm, 0.5 ppm or 0.25 ppm. 
Postupak prema zahtjevu 1, naznačen time da sastav oksikodon hidroklorida ima razinu 14-hidroksikodeinona manju od 5 ppm.
NaHCO3 (sat. aq., 100 mL) was added and the mixture was stirred for 10 min. 
Dodan je NaHCO; (zas.aq, 100 mL) i smjesa se nastavi miješati tijekom 10 minuta.
The residue was purified by column chromatography (SiO2, 5% Et2O in CH2Cl2) to obtain intermediate 40 (4.3 g, 90%) as a clear oil. 
Ostatak je pročišćen kromatografijom na koloni (SiO>, 5 % EtO u CH,C12) da bi se dobio Intermedijer 40 (4.3 g, 90 %) kao bistro ulje.
The microaggregates can be detected by light scattering, and this technique also allows their size to be measured (see below). 
Mikroagregate se može detektirati pomoću raspršenog svjetla i ova tehnika također omogućuje da se izmjeri njihova veličina (vidi dolje).
The heterodimeric antibody of claim 9, wherein the positively charged amino acid residue substitutions in the CH3 domain of the first heavy chain at positions 366 and 351 are both lysine, and the negatively charged amino acid substitutions in the CH3 domain of the second heavy chain at positions 351 and 368 are each aspartic acid (D) or glutamic acid (E). A heterodimeric antibody comprising two heavy chains with CH3 domains wherein, (i) the CH3 domain of the first heavy chain comprises a substitution of the amino acid residue at position 366 as compared to wildtype and according to the EU numbering system, by a positively charged amino acid residue, and the CH3 domain of the second heavy chain comprises substitutions of the amino acid residues at positions 351 and 368 as compared to wildtype and according to the EU numbering system, by negatively charged amino acid residues; or 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što svako od dva varijabilna područja polipeptidnih lanaca koja sadrže CH3 domenu prepoznaje drugačiji ciljni epitop. Heterodimerna molekula koja sadrži CH3 domenu koja se može dobiti postupcima u skladu s bilo kojim od patentnih zahtjeva 1-8. Heterodimerno antitijelo koje sadrži dvije CH3 domene humanog IgG, naznačeno time što jedna od navedene dvije CH3 domene sadrži ostatak asparaginske kiseline (D) na položaju amino-kiseline 351 u skladu s EU sustavom numeracije i ostatak glutaminske kiseline (E) na položaju amino-kiseline 368 u skladu s EU sustavom numeracije i pri čemu druga od navedene dvije CH3 domene sadrži ostatak lizina (K) na položaju amino-kiseline 366 u skladu s EU sustavom numeracije i ostatak lizina (K) na položaju amino-kiseline 351 u skladu s EU sustavom numeracije.
A method for preparing a mixed salt of a water-soluble polymer-active agent conjugate, comprising the steps of: 
Postupak pripreme mješovite soli konjugata polimera topivog u vodi-aktivnog agensa, koji sadrži korake:
In general, lozenge size (in terms of dimensions and shape) should be suitable for parking the lozenge in the buccal cavity. 
Uopćeno, veličina tablete (prema dimenzijama i obliku) trebala bi biti pogodna za smještanje iste u usnu šupljinu.
is a hydrogen atom or an unsubstituted or substituted C1-8 alkyl group; and R3 is a hydrogen atom, an unsubstituted or substituted C1-8 alkyl group, an unsubstituted or substituted C2-8 alkenyl group, an unsubstituted or substituted C2-8 alkynyl group, an unsubstituted or substituted C3-8 cycloalkyl group, an unsubstituted or substituted C6-10 aryl group, an unsubstituted or substituted heterocyclic group, an unsubstituted or substituted C1-8 acyl group, an unsubstituted or substituted (1-imino)C1-8 alkyl group, an unsubstituted or substituted C1-8 alkoxycarbonyl group, an unsubstituted or substituted hydroxyl group, or a cyano group. 
R' je nesupstituirana ili supstituirana hidroksilna skupina, R? je vodikov atom ili nesupstituirana ili supstituirana skupina C,.g alkil i R> je vodikov atom, nesupstituirana ili supstituirana skupina C,.g alkil, nesupstituirana ili supstituirana skupina C2g alkenil, nesupstituirana ili supstituirana skupina Cxg alkinil, nesupstituirana ili supstituirana skupina Cas cikloalkil, nesupstituirana ili supstituirana skupina Co aril, nesupstituirana ili supstituirana heterociklička skupina, nesupstituirana ili supstituirana skupina C,g acil, nesupstituirana ili supstituirana skupina (1-imino)C;g alkil, nesupstituirana ili supstituirana skupina Cia alkoksikarbonil, nesupstituirana ili supstituirana hidroksilna skupina, ili cijano skupina;
The monoclonal antibody or antigen-binding portion thereof of claim 5, wherein the antibody or antigen-binding portion thereof is an antibody or antigen-binding portion thereof according to claim 1 i), and wherein the binding to a conformational or discontinuous epitope on human GDF-15 is binding to a conformational or discontinuous epitope comprised by the amino acid sequences of SEQ ID No: 25 and SEQ ID No: 26. 
Monoklonsko antitijelo ili njegov dio koji se veže na antigen sukladno zahtjevu 5, naznačeno time, da antitijelo ili njegov dio koji se veže na antigen je antitijelo ili njegov dio koji se veže na antigen sukladno zahtjevu 1 i), naznačen time, da vezanje na konformacijski ili diskontinuirani epitop na humanom GDF-15 se veže na konformacijski ili diskontinuirani epitop koji sadrži aminokiselinske sekvence SEQ ID NO: 25 1 SEQ ID NO: 26.
said SMGCC of step a) is mixed with said pigment of step b); and at least one resin is additionally provided and mixed with said SMGCC of step a) and said pigment of step b). 
Cc) navedeni SMGCC 1z koraka a) pomiješa s navedenim pigmentom iz koraka b); zatim dodatno doda najmanje jedna smola i pomiješa s navedenim SMGCC-om iz koraka a) i navedenim pigmentom iz koraka b).
In one embodiment, the present invention provides an antagonistic antibody molecule having specificity for human OX40, which is a modified Fab fragment having a heavy chain comprising or consisting of the sequence given in SEQ ID NO:15 and a light chain comprising or consisting of the sequence given in SEQ ID NO:11 and having an effector molecule attached to the cysteine at position 226 of the heavy chain (linear numbering from SEQ ID NO:15). 
Protutijelo koje ima specifičnost za ljudski OX40 prema zahtjevu 1, naznačeno time što modificirani Fab ulomak ima teški lanac koji sadrži sekvencu navedenu u SEQ ID NO:15 i laki lanac koji sadrži sekvencu navedenu u SEQ ID NO:11 i koji su vezani na cistein na položaju 226 teškog lanca protutijela lizil-maleimidne skupine; pri čemu svaka amino skupina lizilnog ostatka ima na nju kovalentno vezan metoksipoli(etilenglikol) ostatak koji ima molekulsku masu od oko 20,000 Da.